FDA accepts Takeda NDA for zasocitinib under Priority Review
Takeda said the U.S. FDA accepted its NDA under Priority Review for zasocitinib (TAK-279) for adults with moderate-to-severe plaque psoriasis.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.